NLS Pharmaceutics Ltd. Announces Private Placement
Ticker: NCEL · Form: 6-K · Filed: Dec 4, 2024 · CIK: 1783036
| Field | Detail |
|---|---|
| Company | Nls Pharmaceutics LTD. (NCEL) |
| Form Type | 6-K |
| Filed Date | Dec 4, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $3.10, $1 m, $500,000, $500,000 m, $3 |
| Sentiment | neutral |
Sentiment: neutral
Topics: private-placement, financing, shares
TL;DR
NLS Pharma is selling up to 322,580 shares in a private placement to an accredited investor.
AI Summary
On December 4, 2024, NLS Pharmaceutics Ltd. entered into a securities purchase agreement for a private placement offering. The company agreed to issue and sell up to 322,580 common shares, with a par value of CHF 0.80 per share, to an accredited investor.
Why It Matters
This private placement provides NLS Pharmaceutics with capital, potentially to fund its ongoing research and development or operational needs.
Risk Assessment
Risk Level: medium — Private placements can dilute existing shareholders and the terms of the deal, including the price, are not publicly disclosed until later, introducing uncertainty.
Key Numbers
- 322,580 — Common Shares (Maximum number of shares to be issued in the private placement.)
- CHF 0.80 — Par Value (Par value per common share being offered.)
Key Players & Entities
- NLS Pharmaceutics Ltd. (company) — Filer of the report and issuer of shares
- December 4, 2024 (date) — Date of the securities purchase agreement
- 322,580 (dollar_amount) — Maximum number of common shares to be issued
- CHF 0.80 (dollar_amount) — Par value per common share
FAQ
What is the total number of common shares NLS Pharmaceutics Ltd. agreed to issue in the private placement?
NLS Pharmaceutics Ltd. agreed to issue up to 322,580 common shares.
On what date did NLS Pharmaceutics Ltd. enter into the securities purchase agreement?
The securities purchase agreement was entered into on December 4, 2024.
What is the par value of each common share being sold?
The par value of each common share is CHF 0.80.
Who is the counterparty in the securities purchase agreement?
The counterparty is a certain accredited investor.
What type of offering is this transaction?
This transaction is a private placement offering.
Filing Stats: 1,252 words · 5 min read · ~4 pages · Grade level 14.1 · Accepted 2024-12-04 16:13:00
Key Financial Figures
- $3.10 — e Common Shares, at a purchase price of $3.10 per Common Share for aggregate gross pr
- $1 m — e for aggregate gross proceeds of up to $1 million, subject to shareholder approval,
- $500,000 — losing of the Offering in the amount of $500,000 is expected to occur on or before Janua
- $500,000 m — 10, 2025, and the subsequent closing of $500,000 may occur, at the election of the investo
- $3 — rading days above the purchase price of $3.10, which corresponds to an approximate
- $1 million — gross proceeds to the Company of up to $1 million. The Company intends to use the net pro
- $1 Million — s Pricing of Private Placement of up to $1 Million at an Approximate 15% Premium to the Ma
Filing Documents
- ea0223564-6k_nlspharma.htm (6-K) — 20KB
- ea022356401ex99-1_nlspharma.htm (EX-99.1) — 361KB
- ea022356401ex99-3_nlspharma.htm (EX-99.3) — 7KB
- 0001213900-24-105633.txt ( ) — 390KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NLS Pharmaceutics Ltd. Date: December 4, 2024 By: /s/ Alexander Zwyer Name: Alexander Zwyer Title: Chief Executive Officer 3